Clinical Trials Using Gemcitabine Hydrochloride

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gemcitabine Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 90

  • Carboplatin and Gemcitabine Hydrochloride with or without Pembrolizumab in Treating Patients with Metastatic Triple-Negative Breast Cancer

    This randomized phase II trial studies the side effects of carboplatin and gemcitabine hydrochloride with or without pembrolizumab and to see how well they work in treating patients with triple-negative breast cancer that has spread to the other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together with carboplatin and gemcitabine hydrochloride may work better in treating patients with triple-negative breast cancer that has spread to the other places in the body.
    Location: 5 locations

  • Pembrolizumab, Gemcitabine Hydrochloride and Radiation Therapy in Treating Patients with Bladder Urothelial Cancer

    This phase II trial studies how well pembrolizumab, gemcitabine hydrochloride and hypofractionated radiation therapy work in treating patients with bladder urothelial cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Gemcitabine hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving pembrolizumab, gemcitabine hydrochloride and hypofractionated radiation therapy may kill more tumor cells in patients with bladder urothelial cancer.
    Location: 5 locations

  • IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

    This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent, and in patients with peripheral T-cell lymphoma in combination with gemcitabine and oxaliplatin chemotherapy (GEMOX)
    Location: 7 locations

  • ADI-PEG 20, Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Unresectable or Metastatic Soft Tissue Sarcoma, Osteosarcoma, Ewing’s sarcoma, or Small Cell Lung Cancer

    This phase II trial studies how well pegargiminase (ADI-PEG 20) works in combination with gemcitabine hydrochloride and docetaxel in treating patients with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer that cannot be removed surgically (unresectable) or that has spread to other parts of the body (metastatic). ADI-PEG 20 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ADI-PEG 20 with gemcitabine hydrochloride and docetaxel may work better in treating patients with soft tissue sarcoma.
    Location: 4 locations

  • A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

    In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - Progression-free survival (PFS) in the study population.
    Location: 4 locations

  • Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

    This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.
    Location: 4 locations

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer

    This is a Phase Ib / II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced TNBC. The study will be performed in two stages. During Stage 1, two cohorts will be enrolled in parallel in this study: one cohort will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line [1L] PD-L1+ cohort), and one cohort will consist of participants who had disease progression during or following 1L treatment with chemotherapy (e.g., paclitaxel, nab-paclitaxel, carboplatin) and have not received cancer immunotherapy (CIT) (second-line [2L] CIT-naive cohort). In addition, participants in the 2L CIT-naive cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.
    Location: 3 locations

  • Ribociclib and Gemcitabine Hydrochloride in Treating Patients with Advanced or Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of ribociclib and gemcitabine hydrochloride in treating patients with solid tumors that have spread to other places in the body. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and gemcitabine hydrochloride may work better in treating patients with solid tumors.
    Location: 3 locations

  • MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer

    This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
    Location: 3 locations

  • Selinexor, Gemcitabine, and Nab-Paclitaxel in Treating Patients with Metastatic Pancreatic Cancer

    This partially randomized phase Ib / II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 5 locations

  • Surgery and Chemotherapy with or without Chemotherapy after Surgery in Treating Patients with Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

    This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal cancer. Giving a dose of heated chemotherapy into the abdomen during surgery that is done to remove ovarian, fallopian tube, uterine, or peritoneal cancer may help lower the risk of the cancer coming back. Giving unheated chemotherapy drugs directly into the abdomen after surgery may kill more tumor cells.
    Location: 4 locations

  • Atezolizumab and Chemotherapy in Treating Patients with Metastatic or Unresectable and Locally Advanced Urothelial Carcinoma

    This phase II trial studies how well atezolizumab and chemotherapy work in treating patients with urothelial carcinoma that has spread to other places in the body or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, gemcitabine hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab and chemotherapy may work better in treating patients with urothelial carcinoma.
    Location: 2 locations

  • Carbon Ion or Conventional Photon Radiation Therapy and Chemotherapy in Treating Patients with Locally Advanced, Unresectable Pancreatic Cancer

    This phase III trial studies how well carbon ion radiation therapy works compared to conventional photon radiation therapy when giving together with chemotherapy in treating patients with pancreatic cancer that has spread from its original site of growth to nearby tissues or lymph nodes and cannot be removed by surgery. Carbon ion radiation therapy uses charged carbon particles to kill tumor cells and shrink tumors. Conventional photon radiation therapy, such as intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Given carbon ion radiation therapy with chemotherapy may kill more tumor cells in patients with pancreatic cancer compared to conventional photon radiation therapy and chemotherapy.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Paricalcitol, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Metastatic Pancreatic Cancer

    This phase I / II trial studies the side effects and how well paricalcitol, gemcitabine hydrochloride, and nab-paclitaxel work in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Paricalcitol is a form of vitamin D that works by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving paricalcitol, gemcitabine hydrochloride, and nab-paclitaxel may work better in treating patients with metastatic pancreatic cancer.
    Location: 2 locations

  • Nab-paclitaxel followed by Gemcitabine Hydrochloride in Treating Pediatric Participants with Newly-Diagnostic, Relapsed or Refractory Solid Tumors

    This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with gemcitabine hydrochloride in treating pediatric participants with solid tumors that are newly-diagnostic, have come back, or do not respond to treatment. Nab-paclitaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, or by stopping them from dividing, or by stopping them from spreading. Giving nab-paclitaxel in combination with gemcitabine hydrochloride, may work better in treating pediatric participants with solid tumors.
    Location: 2 locations

  • A Phase 1 Dose-escalation Study of FF 10832 for the Treatment of Advanced Solid Tumors

    To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors.
    Location: 2 locations

  • Ascorbic Acid and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Lymphoma

    This randomized phase II trial studies how well ascorbic acid and combination chemotherapy work in treating patients with lymphoma that has come back or does not respond to therapy. Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may work better at treating lymphoma.
    Location: 5 locations

  • Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients with FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer that has come back. Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to a chemotherapy drug called DM4. Mirvetuximab attaches to FOLR1 positive cancer cells in a targeted way and delivers DM4 to kill them. Drugs used in the chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mirvetuximab soravtansine and gemcitabine may work better in treating patients with FRalpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer.
    Location: 2 locations

  • Celecoxib, Gemcitabine Hydrochloride, and Cisplatin in Treating Participants with Bladder Cancer before Surgery

    This phase I trial studies the side effects and how well celecoxib, gemcitabine hydrochloride, and cisplatin work in treating participants with bladder cancer before surgery. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving celecoxib, gemcitabine hydrochloride, and cisplatin before surgery may work better in treating participants with bladder cancer.
    Location: 2 locations

  • Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Avelumab for Non-small Cell Lung Cancer

    This phase Ib / II trial studies the best dose of carboplatin when given together with M6620, gemcitabine and avelumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung cancer. M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving M6620 together with carboplatin, gemcitabine, and avelumab may work better in treating patients with squamous cell non-small cell lung cancer compared to carboplatin, gemcitabine, and avelumab alone.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Gemcitabine and Cisplatin with or without Devimistat as First Line Therapy for the Treatment of Advanced Unresectable Biliary Tract Cancer, BilT-04 Trial

    This phase IB / II trial investigates the side effects and best dose of devimistat and how well it works with gemcitabine and cisplatin as initial treatment (first-line therapy) for patients with biliary tract cancer that has spread to other places in the body (advanced) or cannot be removed by surgery (unresectable). Devimistat may kill tumor cells by turning off their mitochondria. Mitochondria are used by tumor cells to produce energy and are the building blocks needed to make more tumor cells. By shutting off these mitochondria, devimistat may deprive the tumor cells of energy and other supplies that they need to survive and grow in the body. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving devimistat with gemcitabine and cisplatin may kill more tumor cells than giving only gemcitabine and cisplatin.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009 / KEYLYNK-009)

    The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: 1. Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with chemotherapy plus pembrolizumab. 2. Olaparib plus pembrolizumab is non-inferior to chemotherapy plus pembrolizumab in terms of overall survival (OS). 3. Olaparib plus pembrolizumab prolongs OS compared with chemotherapy plus pembrolizumab.
    Location: 2 locations

  • Galeterone Alone or Combined with Gemcitabine for the Treatment of Refractory Metastatic Pancreatic Adenocarcinoma

    This phase II trial studies how well an investigational agent called galeterone works by itself, or in combination with gemcitabine for the treatment of pancreatic cancer that does not respond to standard treatment (refractory) and has spread to other places in the body (metastatic). Galeterone may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Information from this study may help doctors learn more about galeterone and the treatment of metastatic pancreatic cancer, which may benefit patients with the same or a similar condition in the future.
    Location: University of Maryland / Greenebaum Cancer Center, Baltimore, Maryland

  • Gemcitabine and Docetaxel with Radiation Therapy before Surgery for the Treatment of High Grade and Greater than 5 cm Soft Tissue Sarcoma of the Extremities

    This phase I trial investigates the side effects and best dose of gemcitabine and docetaxel when given together with radiation therapy, and to see how well the combination works before surgery in treating patients with high grade soft tissue sarcoma of the upper or lower limbs (extremities) that is over 5 cm in size. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving gemcitabine, docetaxel, and radiation therapy to patients with soft tissue sarcoma of the extremities may lead to a reduction in the size of the tumor prior to surgery. It may also lead to better surgical outcomes and / or reduce the risk of the tumor spreading to other parts of the body.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina

  • Prexasertib with Cyclophosphamide or Gemcitabine in Treating Children and Adolescents with Recurrent or Refractory Medulloblastoma

    This phase I trial studies the side effects and best dose of prexasertib when given together with cyclophosphamide or gemcitabine in treating younger patients with a brain tumor called medulloblastoma that has come back (recurrent) or does not respond to treatment (refractory). Prexasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and gemcitabine , work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving prexasertib in combination with cyclophosphamide and gemcitabine may cause tumors to stop growing or to shrink for a period of time and may lessen the symptoms, such as pain, that are caused by the tumor in patients with medulloblastoma.
    Location: Saint Jude Children's Research Hospital, Memphis, Tennessee